Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies

BACKGROUND: At EU marketing authorisation, safety data for CT-P13 (biosimilar infliximab) were limited, particularly in some indications, and uncommon adverse events (AEs) could not be evaluated among relatively small analysis populations. OBJECTIVES: Our objective was to investigate the overall saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Joon, Baek, KyungMin, Lee, Sujin, Lee, Yoon Jee, Park, Jeong Eun, Lee, Seul Gi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223987/
https://www.ncbi.nlm.nih.gov/pubmed/32356239
http://dx.doi.org/10.1007/s40259-020-00421-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223987/
https://www.ncbi.nlm.nih.gov/pubmed/32356239
http://dx.doi.org/10.1007/s40259-020-00421-2

Ejemplares similares